META vs PFE: Which Is the Better Buy?
Side-by-side comparison of Meta Platforms, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
Meta Platforms, Inc. · Communication Services
$665.60
+21.4% upside to fair value
Med Conviction
Grade B+
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
META has more upside to fair value
(+21.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
META |
PFE |
| Current Price |
$665.60 |
$27.64 |
| Fair Value Estimate |
$808.00 |
$30.94 |
| Upside to Fair Value |
+21.4%
|
+12.0%
|
| Market Cap |
$1,695.6B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
16.7x
|
17.4x
|
| Price / Sales |
7.4x
|
2.5x
|
| Price / FCF |
41.3x
|
14.3x
|
| Revenue Growth YoY |
+28.0%
|
+2.6%
|
| Gross Margin |
81.7%
|
71.3%
|
| Operating Margin |
38.1%
|
25.1%
|
| Return on Equity |
29.7%
|
4.9%
|
| Dividend Yield |
0.32% |
6.22% |
| FCF Yield |
2.42%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Meta Platforms operates the Facebook, Instagram, WhatsApp, Messenger and Threads ecosystem, monetizing its unmatched global audience primarily through digital advertising. Business quality is high, supported by 3.60 billion Family daily active people, AI-enhanced ad ranking, 81.7% TTM gross margin, 38.1% TTM operating margin, 29.8% TTM net margin and 29.7% ROE. Revenue grew 28.0% year over year i…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
META |
PFE |
| Zone Low |
$606.00 |
$23.21 |
| Zone High |
$686.80 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|